High‐density lipoprotein functionality and breast cancer: A potential therapeutic target. Issue 4 (26th October 2018)

• Record Type: Journal Article
• Authors: Samadi, Sara; Ghayour‐Mobarhan, Majid; Mohammadpour, Amirhooshang; Farjami, Zahra; Tabadkani, Mahla; Hosseinnia, Mohammad; Miri, Mehri; Heydari‐Majd, Motahareh; Mehramiz, Mehrane; Rezayi, Majid; Ferns, Gordon A.; Avan, Amir
• Is Part Of: Journal of cellular biochemistry. Volume 120:Issue 4(2019)
• Page Start: 5756
• Page End: 5765
• Publication Date: 2018-10-26
• Subjects: breast cancer -- high‐density lipoprotein function -- high‐density lipoprotein transporter -- reconstituted high‐density lipoprotein -- therapy; Cytochemistry -- Periodicals; 572
• DOI: 10.1002/jcb.27862
• Languages: English
• ISSNs: 0730-2312

Abstract

Abstract: Breast cancer is a major cause of death globally, and particularly in developed countries. Breast cancer is influenced by cholesterol membrane content, by affecting the signaling pathways modulating cell growth, adherence, and migration. Furthermore, steroid hormones are derived from cholesterol and these play a key role in the pathogenesis of breast cancer. Although most findings have reported an inverse association between serum high‐density lipoprotein (HDL)‐cholesterol level and the risk of breast cancer, there have been some reports of the opposite, and the association therefore remains unclear. HDL is principally known for participating in reverse cholesterol transport and has an inverse relationship with the cardiovascular risk. HDL is heterogeneous, with particles varying in composition, size, and structure, which can be altered under different circumstances, such as inflammation, aging, and certain diseases. It has also been proposed that HDL functionality might have a bearing on the breast cancer. Owing to the potential role of cholesterol in cancer, its reduction using statins, and particularly as an adjuvant during chemotherapy may be useful in the anticancer treatment, and may also be related to the decline in cancer mortality. Reconstituted HDLs have the ability to release chemotherapeutic drugs inside the cell. As a consequence, this may be a novel way to improve therapeutic targeting for the breast cancer on the basis of detrimental impacts of oxidized HDL on cancer development.